These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34262990)

  • 1. Cefiderocol Activity Against Clinical
    Simner PJ; Beisken S; Bergman Y; Posch AE; Cosgrove SE; Tamma PD
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab311. PubMed ID: 34262990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.
    Tamma PD; Beisken S; Bergman Y; Posch AE; Avdic E; Sharara SL; Cosgrove SE; Simner PJ
    Clin Infect Dis; 2021 Dec; 73(11):e4599-e4606. PubMed ID: 32881997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
    Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
    J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Shields RK; Kline EG; Squires KM; Van Tyne D; Doi Y
    JAC Antimicrob Resist; 2023 Oct; 5(5):dlad107. PubMed ID: 37795425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of novel β-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis.
    Huang M; Cai F; Liu C; Zheng H; Lin X; Li Y; Wang L; Ruan J
    Am J Infect Control; 2024 Jul; 52(7):774-784. PubMed ID: 38428591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of
    Wang L; Zhang X; Zhou X; Yang F; Guo Q; Wang M
    Microbiol Spectr; 2023 Jun; 11(3):e0093223. PubMed ID: 37199669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
    Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
    Lin LY; Debabov D; Chang W; Stone G; Riccobene T
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
    [No Abstract]   [Full Text] [Related]  

  • 11. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
    Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G
    J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.
    Fernández-Esgueva M; López-Calleja AI; Mulet X; Fraile-Ribot PA; Cabot G; Huarte R; Rezusta A; Oliver A
    Enferm Infecc Microbiol Clin (Engl Ed); 2020 Dec; 38(10):474-478. PubMed ID: 32143893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
    J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E; Genc L; Cyr EA; Karakus M; Comert F; Otlu B; Aktas E; Nicolau DP
    Eur J Clin Microbiol Infect Dis; 2024 Sep; 43(9):1787-1794. PubMed ID: 38995343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21.
    Karlowsky JA; Lob SH; Bauer KA; Esterly J; Siddiqui F; Young K; Motyl MR; Sahm DF
    JAC Antimicrob Resist; 2024 Feb; 6(1):dlad152. PubMed ID: 38222461
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Rubio AM; Kline EG; Jones CE; Chen L; Kreiswirth BN; Nguyen MH; Clancy CJ; Cooper VS; Haidar G; Van Tyne D; Shields RK
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
    Arca-Suárez J; Lasarte-Monterrubio C; Rodiño-Janeiro BK; Cabot G; Vázquez-Ucha JC; Rodríguez-Iglesias M; Galán-Sánchez F; Beceiro A; González-Bello C; Oliver A; Bou G
    J Antimicrob Chemother; 2021 Jan; 76(1):91-100. PubMed ID: 33083833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility profile and β-lactamase content of global
    Karlowsky JA; Lob SH; Estabrook MA; Siddiqui F; DeRyke CA; Young K; Motyl MR; Sahm DF
    JAC Antimicrob Resist; 2023 Jun; 5(3):dlad080. PubMed ID: 37388237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.